Deutsche Bank Ag\ Aldeyra Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$245 Billion
Q1 2025

A detailed history of Deutsche Bank Ag\ transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 314,423 shares of ALDX stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

314,423

Previous 319,287 1.52%

Holding current value

$1.23 Million

Previous $1.59 Million 13.43%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$4.7 - $6.98 $22,860 - $33,950	-4,864 Reduced 1.52%	314,423 $1.81 Million
Q4 2024 Feb 14, 2025	BUY	$4.21 - $5.9 $78,710 - $110,306	18,696 Added 6.22%	319,287 $1.59 Million
Q3 2024 Jun 26, 2025	SELL	$3.19 - $6.32 $44,124 - $87,418	-13,832 Reduced 4.4%	300,591 $1.62 Million
Q3 2024 Nov 13, 2024	BUY	$3.19 - $6.32 $762 - $1,510	239 Added 0.08%	300,591 $1.62 Million
Q2 2024 Jun 12, 2025	SELL	$3.25 - $4.72 $45,730 - $66,415	-14,071 Reduced 4.48%	300,352 $994,000
Q2 2024 Aug 14, 2024	BUY	$3.25 - $4.72 $25,886 - $37,594	7,965 Added 2.72%	300,352 $994,000
Q1 2024 Jun 02, 2025	SELL	$2.77 - $4.22 $61,039 - $92,991	-22,036 Reduced 7.01%	292,387 $956,000
Q1 2024 May 15, 2024	SELL	$2.77 - $4.22 $13,985 - $21,306	-5,049 Reduced 1.7%	292,387 $956,000
Q4 2023 Feb 14, 2024	BUY	$1.47 - $6.06 $3,911 - $16,125	2,661 Added 0.9%	297,436 $1.04 Million
Q3 2023 Nov 09, 2023	BUY	$6.11 - $8.16 $39,531 - $52,795	6,470 Added 2.24%	294,775 $1.97 Million
Q2 2023 Aug 14, 2023	BUY	$7.11 - $11.89 $456,824 - $763,944	64,251 Added 28.68%	288,305 $2.42 Million
Q1 2023 May 15, 2023	SELL	$5.77 - $9.93 $31,157 - $53,622	-5,400 Reduced 2.35%	224,054 $2.22 Million
Q2 2022 Aug 11, 2022	SELL	$2.43 - $4.85 $161,286 - $321,909	-66,373 Reduced 22.44%	229,454 $916,000
Q1 2022 May 13, 2022	BUY	$3.25 - $5.17 $113,265 - $180,179	34,851 Added 13.35%	295,827 $1.32 Million
Q4 2021 Feb 11, 2022	BUY	$3.5 - $9.63 $5,432 - $14,945	1,552 Added 0.6%	260,976 $1.04 Million
Q3 2021 Nov 04, 2021	SELL	$7.94 - $11.31 $7,146 - $10,179	-900 Reduced 0.35%	259,424 $2.28 Million
Q2 2021 Aug 11, 2021	SELL	$10.44 - $14.85 $410,385 - $583,738	-39,309 Reduced 13.12%	260,324 $2.95 Million
Q4 2020 Feb 16, 2021	BUY	$6.31 - $8.13 $753,470 - $970,795	119,409 Added 66.26%	299,633 $2.06 Million
Q3 2020 Nov 12, 2020	BUY	$4.0 - $7.53 $402,668 - $758,022	100,667 Added 126.53%	180,224 $1.34 Million
Q2 2020 Aug 13, 2020	BUY	$1.97 - $5.05 $124,307 - $318,655	63,100 Added 383.42%	79,557 $332,000
Q1 2020 May 14, 2020	SELL	$1.62 - $6.4 $28,260 - $111,648	-17,445 Reduced 51.46%	16,457 $40,000
Q4 2019 Feb 14, 2020	BUY	$4.73 - $7.98 $88,649 - $149,561	18,742 Added 123.63%	33,902 $195,000
Q3 2019 Nov 14, 2019	SELL	$4.41 - $6.12 $51,694 - $71,738	-11,722 Reduced 43.61%	15,160 $79,000
Q2 2019 Aug 14, 2019	SELL	$6.0 - $9.0 $52,596 - $78,894	-8,766 Reduced 24.59%	26,882 $160,000
Q1 2019 May 15, 2019	SELL	$7.14 - $9.85 $28,631 - $39,498	-4,010 Reduced 10.11%	35,648 $321,000
Q4 2018 Feb 14, 2019	BUY	$7.26 - $13.29 $9,285 - $16,997	1,279 Added 3.33%	39,658 $328,000
Q3 2018 Dec 21, 2021	BUY	$6.8 - $14.35 $30,423 - $64,201	4,474 Added 13.2%	38,379 $530,000
Q3 2018 Nov 14, 2018	BUY	$6.8 - $14.35 $22,773 - $48,058	3,349 Added 10.96%	33,905 $466,000
Q2 2018 Apr 21, 2020	BUY	$6.95 - $9.18 $35,917 - $47,442	5,168 Added 20.36%	30,556 $243,000
Q2 2018 Aug 14, 2018	BUY	$6.95 - $9.18 $176,446 - $233,061	25,388 New	25,388 $201,000
Q1 2018 May 15, 2018	SELL	$6.55 - $8.9 $11,135 - $15,130	-1,700 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$5.7 - $7.75 $35,910 - $48,825	-6,300 Reduced 78.75%	1,700 $11,000
Q3 2017 Nov 14, 2017	BUY	$3.9 - $10.8 $31,200 - $86,400	8,000	8,000 $57,000

Others Institutions Holding ALDX

# of Institutions

139

Shares Held

38.6M

Call Options Held

620K

Put Options Held

435K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $227M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account